Clayton A Smith1,2, Courtney McCracken1,2, Amanda S Thomas1, Logan G Spector3, James D St Louis4, Matthew E Oster1,2, James H Moller5, Lazaros Kochilas1,2. 1. Department of Pediatrics, Emory University School of Medicine. 2. Children's Healthcare of Atlanta, Atlanta, Georgia. 3. Department of Pediatrics, University of Minnesota, Minneapolis. 4. Department of Pediatric Surgery, University of Missouri, Kansas City School of Medicine. 5. Department of Internal Medicine, University of Minnesota, Minneapolis.
Abstract
Importance: Tetralogy of Fallot (TOF) is a surgically repairable form of cyanotic congenital heart disease. Multicenter data for long-term survival following repair are sparse. Objective: To evaluate the long-term transplant-free survival of TOF by surgical strategy adjusted for era and patient characteristics. Design, Setting, and Participants: Retrospective cohort study enriched with data from the National Death Index and the Organ Procurement and Transplantation Network through 2014. Multicenter cohort from the Pediatric Cardiac Care Consortium (PCCC), a large, US-based clinical registry for interventions for congenital heart disease. The cohort included patients with adequate identifiers for linkage with the National Death Index and the Organ Procurement and Transplantation Network who were enrolled in the PCCC registry between 1982 and 2003 and survived surgical repair of simple TOF. Data were analyzed between September 2015 and April 2018. Exposures: We examined patient-associated and surgery-associated risk factors affecting survival. Main Outcomes and Measures: We analyzed the transplant-free survival during early (<6 years) and late (≥6 years) phase after TOF surgical repair. Results: Of the 3283 patients who survived repair for simple TOF and met the study's inclusion criteria, 56.4% were male and 43.6% were female. Twenty-five-year survival following TOF repair was 94.5%. Multivariable analysis demonstrated increased risk of early mortality with staged repair (HR, 2.68; 95% CI, 1.59-4.49) and non-valve-sparing operation (HR, 3.76; 95% CI, 1.53-9.19). Presence of a genetic abnormality was associated with increased risk of death both in the early (HR, 3.64; 95% CI, 2.05-6.47) and late postoperative phase (HR, 4.41; 95% CI, 2.62-7.44). Conclusions and Relevance: Long-term survival after simple TOF repair is excellent. Staged repair and non-valve-sparing operations were negatively associated with survival in the early postrepair phase but not the late postrepair phase. These data are important for patients with repaired TOF and their caretakers and may guide surgical strategies for optimizing the long-term outcomes of this population.
Importance: Tetralogy of Fallot (TOF) is a surgically repairable form of cyanotic congenital heart disease. Multicenter data for long-term survival following repair are sparse. Objective: To evaluate the long-term transplant-free survival of TOF by surgical strategy adjusted for era and patient characteristics. Design, Setting, and Participants: Retrospective cohort study enriched with data from the National Death Index and the Organ Procurement and Transplantation Network through 2014. Multicenter cohort from the Pediatric Cardiac Care Consortium (PCCC), a large, US-based clinical registry for interventions for congenital heart disease. The cohort included patients with adequate identifiers for linkage with the National Death Index and the Organ Procurement and Transplantation Network who were enrolled in the PCCC registry between 1982 and 2003 and survived surgical repair of simple TOF. Data were analyzed between September 2015 and April 2018. Exposures: We examined patient-associated and surgery-associated risk factors affecting survival. Main Outcomes and Measures: We analyzed the transplant-free survival during early (<6 years) and late (≥6 years) phase after TOF surgical repair. Results: Of the 3283 patients who survived repair for simple TOF and met the study's inclusion criteria, 56.4% were male and 43.6% were female. Twenty-five-year survival following TOF repair was 94.5%. Multivariable analysis demonstrated increased risk of early mortality with staged repair (HR, 2.68; 95% CI, 1.59-4.49) and non-valve-sparing operation (HR, 3.76; 95% CI, 1.53-9.19). Presence of a genetic abnormality was associated with increased risk of death both in the early (HR, 3.64; 95% CI, 2.05-6.47) and late postoperative phase (HR, 4.41; 95% CI, 2.62-7.44). Conclusions and Relevance: Long-term survival after simple TOF repair is excellent. Staged repair and non-valve-sparing operations were negatively associated with survival in the early postrepair phase but not the late postrepair phase. These data are important for patients with repaired TOF and their caretakers and may guide surgical strategies for optimizing the long-term outcomes of this population.
Authors: E A Bacha; A M Scheule; D Zurakowski; L C Erickson; J Hung; P Lang; J E Mayer; P J del Nido; R A Jonas Journal: J Thorac Cardiovasc Surg Date: 2001-07 Impact factor: 5.209
Authors: Logan G Spector; Jeremiah S Menk; Jessica H Knight; Courtney McCracken; Amanda S Thomas; Jeffrey M Vinocur; Matthew E Oster; James D St Louis; James H Moller; Lazaros Kochilas Journal: J Am Coll Cardiol Date: 2018-05-29 Impact factor: 24.094
Authors: C W Lillehei; R L Varco; M Cohen; H E Warden; V L Gott; R A DeWall; C Patton; J H Moller Journal: Ann Surg Date: 1986-10 Impact factor: 12.969
Authors: David L S Morales; Farhan Zafar; Jeffrey S Heinle; Elena C Ocampo; Jeffrey J Kim; Katherine Relyea; Charles D Fraser Journal: Ann Surg Date: 2009-10 Impact factor: 12.969
Authors: Logan G Spector; Jeremiah S Menk; Jeffrey M Vinocur; Matthew E Oster; Brian A Harvey; James D St Louis; James Moller; Lazaros K Kochilas Journal: J Am Heart Assoc Date: 2016-08-09 Impact factor: 5.501
Authors: Nickolas Forsch; Sachin Govil; James C Perry; Sanjeet Hegde; Alistair A Young; Jeffrey H Omens; Andrew D McCulloch Journal: J Comput Sci Date: 2020-09-19
Authors: Bryan H Goldstein; Christopher J Petit; Athar M Qureshi; Courtney E McCracken; Michael S Kelleman; George T Nicholson; Mark A Law; Jeffery J Meadows; Jeffrey D Zampi; Shabana Shahanavaz; Christopher E Mascio; Paul J Chai; Jennifer C Romano; Sarosh P Batlivala; Shiraz A Maskatia; Ivor B Asztalos; Alicia M Kamsheh; Steven J Healan; Justin D Smith; R Allen Ligon; Joelle A Pettus; Sarina Juma; James E B Raulston; Krissie M Hock; Amy L Pajk; Lindsay F Eilers; Hala Q Khan; Taylor C Merritt; Matthew Canter; Stephan Juergensen; Fatuma-Ayaan Rinderknecht; Holly Bauser-Heaton; Andrew C Glatz Journal: J Am Coll Cardiol Date: 2021-03-02 Impact factor: 24.094
Authors: Timothy E Nissen; Isabella Zaniletti; R Thomas Collins; Lawrence E Greiten; Parthak Prodhan; Paul M Seib; Elijah H Bolin Journal: Pediatr Cardiol Date: 2021-07-30 Impact factor: 1.655